Kissei Pharma licenses Tavalisse for Japan, China, South Korea nd Taiwan.- Rigel Pharmaa
Rigel Pharmaceuticals, Inc. announced that it had entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ) to develop and commercialize Tavalisse in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. Kissei is a Japan-based pharmaceutical company addressing patients' unmet medical needs through its research, development and commercialization efforts, as well as through collaborations with partners.
Tavalisse is commercially available in the U.S. for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins